Global interest in the transmissibility of SARS-CoV-2 and the requirement for safe research are what drove Labskin’s approach.
The webinar began with Labskin’s Head of Sales Eric Clarke introducing the client-facing team to explain what Labskin is, our various skin models and the research services that we provide. Eric detailed the history of Labskin and how the team has developed different 3D skin models for testing, not only the skin microbiome but also the scalp microbiome, vaginal microbiome and infant microbiome to name just a few.
Eric introduced Labskin’s Head of R&D David Caballero-Lima to the attendees. David is key to the collaborative work on Covid we carried out with the University of Aberdeen in their CL3 laboratory facility.
David explained the team was well placed to work with SARS-CoV-2, having previously worked on pathogens such as Ebola. David continued by showing how tests on the Labskin model were carried out. Using comparable studies from the skin model with no sanitiser, and then with various strength sanitisers, he was able to visually highlight how the Labskin model can be used instead of human volunteers for clinical testing.
This research has led the team from Labskin to create a protocol for testing the efficacy, safety and formulation optimisation of hand sanitisers for their clients.
The aim is to ensure hand sanitisers and hand cleansers that claim to have SARS-Cov-2 capabilities can be proven and will open the door to new formulations designed for different skin-types.
The webinar was a resounding success, and the Labskin team would like to offer their appreciation to all who attended. Further details on the work with SARS-CoV-2 that Labskin is undertaking will be available soon.
If you would like to receive the presentation from the webinar, please send a request to us at email@example.com.
Further information on our services can be found at www.labskin.co.uk